Circular RNAs and gastrointestinal cancers: Epigenetic regulators with a prognostic and therapeutic role by Naeli, P. et al.
Contents lists available at ScienceDirect
Critical Reviews in Oncology / Hematology
journal homepage: www.elsevier.com/locate/critrevonc
Circular RNAs and gastrointestinal cancers: Epigenetic regulators with a
prognostic and therapeutic role
Parisa Naelia,1, Mohammad Hossein Pourhanifehb,1, Mohammad Reza Karimzadehc,
Zahra Shabaninejadd,e, Ahmad Movahedpourf,g, Hossein Tarrahimofradh, Hamid Reza Mirzaeii,
Hassan Hassani Bafranij, Amir Savardashtakie,f, Hamed Mirzaeik,*, Michael R. Hamblinl,*
a Department of Biological Sciences, Faculty of Genetics, Tarbiat Modares University, Tehran, Iran
bHalal Research Center of IRI, FDA, Tehran, Iran
c Department of Medical Genetics, School of Medicine, Bam University of Medical Sciences, Bam, Iran
dDepartment of Nanobiotechnology, School of Basic Sciences, TarbiatModares University, Tehran, Iran
e Pharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
fDepartment of Medical Biotechnology, School of Advanced Medical Sciences and Technologies, Shiraz University of Medical Sciences Shiraz, Iran
g Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran
hDepartment of Animal Biotechnology, National Institute of Genetic Engineering and Biotechnology (NIGEB), Tehran, Iran
iDepartment of Medical Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
jAnatomical Sciences Research Center, Institute for Basic Sciences, Kashan University of Medical Sciences, Kashan, Iran
k Research Center for Biochemistry and Nutrition in Metabolic Diseases, Institute for Basic Sciences, Kashan University of Medical Sciences, Kashan, Iran
lWellman Center for Photomedicine, Massachusetts General Hospital, Harvard Medical School, 40 Blossom Street, Boston, MA, 02114, USA
A R T I C L E I N F O
Keywords:
Circular RNAs
Gastrointestinal cancers
microRNA sponge
Prognostic indicator
Biomarkers
Signaling pathways
A B S T R A C T
Both environmental and genetic factors are involved in the initiation and development of gastrointestinal cancer.
Covalent closed circular RNAs (circRNAs) are produced by a mechanism called "back-splicing" from mRNAs.
They are highly stable and show cell and tissue speciﬁc expression patterns. Although some functions such as
"microRNA sponge" and "RNA binding protein sponge" have been reported for a small number of circRNAs, the
function of thousands of other circRNAs is still unknown. Dysregulation of circRNAs has been reported in many
GI cancers and are involved in metastasis and invasion. CircRNAs have been reported to be useful as prognostic
markers and targets for developing new treatments. We ﬁrst describe the properties and biogenesis of circRNAs.
We then summarize recent reports about circRNA functions, expression status, and their potential to be used as
biomarkers in GI cancers including, gastric cancer, colorectal cancer, esophageal cancer, hepatocellular carci-
noma, gallbladder cancer and pancreatic cancer.
1. Introduction
Gastrointestinal (GI) cancers can originate from the stomach, eso-
phagus, pancreas, hepatobiliary system, large intestine (colorectal and
anal regions) and together comprise a major cause of cancer-related
mortality worldwide (Siegel et al., 2019). Smoking, obesity, Helico-
bacter pylori, hepatitis B virus (HBV) and hepatitis C virus (HCV) are
known environmental risk factors for GI cancer development
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(Pourhoseingholi et al., 2015). Genetic factors such as, APC mutation
predisposing to familial adenomatous polyposis (Leoz et al., 2015;
Nallamilli and Hegde, 2017), and mutations in E-cadherin leading to
hereditary diﬀuse-type gastric cancer (Brooks-Wilson et al., 2004; Liu
and Chu, 2014) are known risk factors for GI development, but the
exact molecular mechanisms underlying the progression and malig-
nancy of other GI cancers remain largely unknown. Despite the success
of chemotherapy in the treatment of some GI cancers, many patients
continue to have a bad outcome and the 5-year survival rate in gastric
cancer is less than 10 % (Orditura et al., 2014; Sitarz et al., 2018). It is
important to identify predictive and prognostic biomarkers to improve
current treatment strategies and extend the 5-year survival rate.
CircRNAs are a group of single-stranded RNAs molecules that form a
covalently closed loop structure as a result of joining the 3′ and 5′ ends.
The existence of circRNAs has been known for more than 20 years
(Nigro et al., 1991), but they have generally been considered to be
artifacts of aberrant splicing (Cocquerelle et al., 1993). The ﬁrst cir-
cRNA was serendipitously identiﬁed in a study that aimed to under-
stand how viroids function as plant pathogens (Sanger et al., 1976). It
was found by electron microscopy that viroid RNA is a single-stranded
circular RNA which does not code for any proteins (Gross et al., 1978).
Hepatitis delta was the second virus which was identiﬁed as a circular
RNA, and in this case the circRNA encoded an open reading frame
(ORF) which was translated to a protein (Kos et al., 1986). The ﬁrst
endogenously produced circRNA detected in human cells was a tran-
script of the DCC gene (deleted in colorectal cancer), which was iden-
tiﬁed in the early 1990s. The authors identiﬁed a transcript with the
exons not in the expected order (Nigro et al., 1991). In the next two
decades shuﬄed exons in transcripts of other genes such as SRY (sex-
determining region Y) (Capel et al., 1993) and cytochrome P450 2C24
(CYPIIC24) (Zaphiropoulos, 1993, 1996) were also identiﬁed. However,
recent work has revealed a large number of circRNAs in mammalian
cells, and most of them are stable (Guo et al., 2014a; Rybak-Wolf et al.,
2015; Salzman et al., 2012). Most circRNAs in humans arise from
coding genes (Wilusz, 2017). These transcripts are regulated in-
dependently from the linear transcripts of the underlying gene, and
their transcription levels vary in a cell-speciﬁc manner (Salzman et al.,
2013, 2012).
Studies have shown that circRNAs have some common properties.
Exonic circRNAs are very stable and most of them have half-lives longer
than 48 h inside cells, in comparison to mRNAs that show average half-
lives about 10 h (Jeck et al., 2013; Schwanhausser et al., 2011). How-
ever, circRNAs are not stable in serum, which could be due to the
presence of circulating RNA endonucleases (Haupenthal et al., 2006).
Their stability inside cells is because of their resistance to exonucleases.
This resistance may explain why some circRNAs are more abundant
than the linear RNA products of their respective genes (Salzman et al.,
2012). CircRNAs do not contain the 2′-5′ linkage which is present in
RNA lariats, and are therefore resistant to RNA debranching enzymes.
Using diﬀerent methods, some studies reported that exonic circRNAs
localize in the cytoplasm, and they were susceptible to the siRNA-
mediated decay system, which could be useful in clarifying the func-
tional roles of circRNAs (Hansen et al., 2011). The human homologs of
the Drosophila melanogaster Hel25E (helicase at 25E) similarly regulate
circRNA localization, and their export from the nucleus to cytoplasm is
size dependent (Azmi, 2018; Huang et al., 2018a). Exonic circRNAs
share some sequence-dependent features. The circRNAs that have been
described to date all involve a GT-AG pair of canonical splice sites, but
this could be unreliable because of the detection methods employed
(Jeck et al., 2013). Moreover, some ﬂanking introns are smaller than
the average size, but most are usually longer than introns on average
(Salzman et al., 2013). Lastly, the length of the exons inﬂuences the
circularization, and in circRNAs comprising a single exon, the given
exon was found to be three fold longer compared to all expressed exons
(Jeck and Sharpless, 2014).
The lack of the free 3ʹ end in the circRNA molecule, which is needed
for polyadenylation to take place, prevents researchers from using
many molecular techniques that work by adding a poly-A tail to the
RNA molecule. This makes it diﬃcult to detect circRNAs and to explore
their function. Moreover, because of the backsplicing process, the ar-
rangements of exons are not in the expected order, and circRNAs are
usually ﬁltered out in sequencing algorithms. These problems in
circRNA detection have been overcome with new bioinformatics tools
such as, exonuclease-based enrichment approaches and sequencing of
ribosomal RNA (rRNA)-depleted RNA libraries (instead of polyA-en-
riched libraries) (Jeck and Sharpless, 2014).
Although they have been thought to be a class of non-coding RNAs,
some studies have shown that these circRNAs could also act as mRNAs
and be translated to produce functional proteins. Moreover this process
could be tissue-dependent (Meganck et al., 2018). CircRNAs have been
reported to be associated with ribosomes, and it has been reported that
circRNAs from the muscleblind locus could encode a protein (Pamudurti
et al., 2017). More recently, several studies have reported that dys-
function or dysregulation of circRNAs could be associated with the
development of human diseases including Alzheimer’s (Akhter, 2018)
and cancer (He et al., 2017). CircRNAs could act either as tumor sup-
pressor genes or as oncogenes in cancer initiation and development. In
this review we focus on new ﬁndings concerning circRNA function in
gastrointestinal (GI) cancers and their potential as biomarkers and
prognostic factors.
2. Circular RNA biogenesis
CircRNAs are produced during a unique type of splicing -called
back-splicing- which is catalyzed by canonical spliceosomal machinery
(Vicens and Westhof, 2014). They are formed whenthe 5' and 3' ends of
transcribed exons and/or introns are joined covalently. During this
process, down-stream splice site of donor exon/intron joins to the up-
stream splice site of acceptor exon/intron in a pre-mRNA molecule
(Fig. 1) (Ragan et al., 2019). Several splice variants of circRNA tran-
scripts could be generated from a single gene depending on which exons
are selected by alternative back-splice site selection during the back-
splicing process (Zhang et al., 2016). There are two types of alternative
back-splicing; (a) 5' back-splicing and (b) 3' back-splicing. In the 5' al-
ternative back-splicing, two or more downstream splice sites are al-
ternatively linked to the up-stream 3' splice site. On the other hand, in
the 3' alternative back-splicing, two or more up-stream 3' splice sites are
alternatively linked to the down-stream 5' splice site (Zhang et al.,
2016). The expression level of circRNAs is regulated at three diﬀerent
stages, including transcription, back-splicing regulation, and circRNA
turnover (Li et al., 2018f, g).
Regulation of circRNA generation depends on cis-regulatory ele-
ments and trans-acting factors (Li et al., 2018f, g). Cis-regulatory ele-
ments are the same in all tissues and cells, and the tissue-speciﬁc pat-
tern of circRNA expression suggests that trans-factors must be involved
in regulation of circRNA expression (Zhang et al., 2016). Splicing ma-
chinery, RNA binding proteins, and repeated sequences, such as the Alu
transposable element which is inverted (oriented in opposite direction)
in the RNA can modulate the biogenesis of circRNA (Zhang et al.,
2014). Back-splicing and linear splicing compete with each other in
newly-synthesized RNA in a cell-speciﬁc manner (Ashwal-Fluss et al.,
2014). CircRNAs biogenesis is not yet fully understood, but three main
pathways have been identiﬁed. Exonic circRNA arise from exons and
can be subdivided into two groups: single exon circRNAand multiple
exon circRNA. The second group of circRNAs are exon-intron circRNAs
(EIciRNA) which contain both intron and exon sequences. Intronic
circRNAs originate from the introns of the underlying gene. Analysis of
the splice sites in circRNAs has revealed that most exonic circRNAs
contain canonical GT/AG splicing sites (Shen et al., 2015b). However
the mechanism of splice-site selection in circularization by spliceo-
somes is poorly understood.
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3. CircRNAs function
All the functions of circRNAs have not been fully elucidated, but
some biological functions (especially in gene regulation) have been
proposed (Fig. 2). Their diversity, abundance and conservation suggest
that they may play key roles in cell physiology (Lasda and Parker,
2014). Several functions such as the microRNA sponge and transcrip-
tion regulators have been proposed for circRNAs (Holdt et al., 2018)
Based on competitive endogenous RNA (ceRNA) hypothesis, some
transcripts with shared microRNA binding site compete for microRNA
and post-transcriptional control (Thomson and Dinger, 2016). It was
proposed that circRNAs could act as a decoy for binding to microRNAs,
hence increasing the level of the microRNA target genes (Figure 3). The
ﬁrst example of a circRNA acting as a microRNA sponge, was cir-
cRNACDR1as which could be viewed as an extreme example as itcon-
tained>70 microRNA binding sites for mir-7. Decreasing the level of
CDR1as led to a decreased level of CDR1 mRNA (Hansen et al., 2011).
This regulatory pathway was proposed to play a role in tumorigenesis
and in the mammalian brain (Kleaveland et al., 2018; Xu et al., 2018).
Likewise, the circular SRY contained 16 binding sites for miR-138, and
it co-precipitated with Argonaute-2 (Ago-2) which is a key protein in
the microRNA regulatory pathway (Hansen et al., 2013). These two are
extreme examples of the microRNA sponging activity of circRNAs, and
most other circRNAs contain a much smaller number of microRNA
binding sites.
Some studies have reported that circRNAs can regulate gene tran-
scription. Nuclear localized circRNAs can interact with the complex
between RNA polymerase II and U1 snRNP (small nuclear ribonucleo-
protein) that acts as a regulator of transcription and splicing machinery
(Maiti et al., 2017). Some circRNAs regulate splicing and promote cir-
cularization thereby decreasing linear mRNA levels (Bose and Ain,
2018). CircRNAs could also regulate gene expression (and even its own
expression) at a post-transcriptional level by acting as a RNA binding
protein sponge. CircRNAs have some properties, which suggest they
Fig. 1. CircRNAs biogenesis. Exons are shown as rectangles with diﬀerent colors, and introns are depicted as black lines. Exon-derived circRNA (ecRNA) contains
only exons (A and B), while circular intronic RNA (ciRNA) comprises only introns (D). In exon–intron circRNA (EIciRNA), an intron is introduced between two exons
(C). The pathway by which mature ecRNAs are exported into the cytoplasm is still unclear. Some circRNAs are assumed to pass through the nuclear membrane via a
nuclear pore complex.
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might act as scaﬀolds for RNA binding proteins (Dudekula et al., 2016;
Zang et al., 2018). They may have roles as sequence targeting elements,
which could simultaneously bind to RNA binding proteins and also to
complementary sequences in target RNA or DNA molecules. However,
the function of thousands of other circRNAs has not yet been elucidated
and awaits further study.
4. Circular RNAs as biomarkers
Hulka et al. have deﬁned biomarkers as “cellular, biochemical or
molecular alterations, which can be measured in biological media, in-
cluding human tissues, cells, or ﬂuids". However, recently researchers
have extended the above deﬁnition to cover biological processes, which
may be objectively measured and assessed as indices of normal or
Fig. 2. Schematic illustration of circRNA functions. (A) CircRNAs might function as miRNA sponges by competing for binding of miRNA sequences, lessening the
impact of miRNA-mediated regulationon gene expression. (B) CircRNAs might function as protein sponges, by binding to other RNA-binding proteins (RBPs). (C)
Some circRNAs might control the expression of proteins by sequestering mRNA translation start sites. (D) CircRNAs might be translated to create functional proteins.
(E) CircRNAs (e.g., EIciRNAs and ciRNAs) might interact with transcription complexes and increase the expression of their parental genes.
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pathogenic biological parameters, or responses to therapeutic inter-
ventions (Mayeux, 2004; Naylor, 2003).
Based on the National Cancer Institute, a biomarker is “a biological
molecule found in blood, other body ﬂuids, or tissues, which could be a
marker of a normal or abnormal process, or of a condition or disease”
such as cancer (Henry and Hayes, 2012). In general, biomarkers could
diﬀerentiate an aﬀected individual from a healthy individual (Henry
and Hayes, 2012). Studies have identiﬁed a diverse range of bio-
markers, such as proteins (enzymes or receptors) (Álvarez-Chaver et al.,
2007; Watabe-Rudolph et al., 2012), nucleic acids (microRNAs or other
non-coding RNAs) (Witwer, 2015; Zhou et al., 2015), antibodies
(Schwarz et al., 2006), and peptides (Belogurov et al., 2008). Moreover,
a biomarker may also consist of a set of modiﬁcations, including me-
tabolomic and proteomic signatures, and gene expression proﬁles. It
should be noted that many biomarkers are capable of being detected in
the circulation: (serum, plasma, or whole blood); or in excretions or
secretions (urine, stool, nipple discharge, or sputum). For this reason,
they can be readily evaluated in a non-invasive serial manner. Other
biomarkers may be only detectable in whole tissue, in which case, they
would need special imaging or biopsies to be evaluated (Henry and
Hayes, 2012).
Contemporary studies have shown that many features of circRNAs
enable them to serve as biomarkers for some human diseases (Conn
et al., 2015). One of these features is their stability. As a result of the
covalently closed-loop structure with no free 5′ and 3′ ends, circRNA
molecules show high resistance to the exonuclease RNase R compared
to linear RNAs (Enuka et al., 2015; Memczak et al., 2013). Other studies
have found that the average half-life of circRNAs in plasma exceeds
48 h, which is much longer than the average half life of mRNAs (10 h)
(Jeck and Sharpless, 2014; Zhong et al., 2018c). Another feature is
universality. According to some researchers, circRNAs are among the
most universal molecules found in human cells (Salzman et al., 2012).
circRNAs can be more abundant than their linear isoforms under some
conditions (Glažar et al., 2014). Moreover, circRNA is more abundant
in the brain compared to other organs (Rybak-Wolf et al., 2015). The
relatively high concentration of circRNAs in the blood could be ascribed
to their high stability (Li et al., 2018c; Memczak et al., 2015). Another
advantageous feature is speciﬁcity; that is, the circRNAs are expressed
in a tissue-speciﬁc and developmental stage-speciﬁc manner. This
characteristic makes circRNAs useful bio-markers for particular dis-
eases. Several studies have found that circRNAs are diﬀerentially ex-
pressed between cancerous and noncancerous tissues (Memczak et al.,
2013) and that there identity and abundance are also distinctive of
cancer cells (Floris et al., 2017; Salzman et al., 2013). Finally, circRNAs
are strongly conserved across various species, meaning that a number of
circRNA biomarkers that have been detected in murine models are also
candidates for translation to clinical applications in humans (Jeck et al.,
2013).
5. GI cancers and circRNAs
The aberrant expression of circRNAs has been linked to many
human diseases including cancer (He et al., 2017). CircRNAs are be-
coming an interesting subject in cancer research due to their abun-
dance, stability and regulatory function. To date some circRNAs have
been implicated with several hallmarks of cancer, such as cell death and
survival, invasion, metastasis and angiogenesis (Kristensen et al.,
2018). These circRNAs can be detected in body ﬂuids such as saliva and
blood, and also in exosomes, suggesting that they could be used as non-
invasive biomarkers in cancer detection (Bahn et al., 2015; Memczak
et al., 2015; Qian et al., 2018; Wang et al., 2016). The role of circRNAs
in GI cancers remains unknown, but some studies have shown that they
are diﬀerentially expressed, and could be linked with prognosis, stage
determination, and 5-year survival. The results have similarities and
diﬀerences between studies, which could be due to diﬀerent sample
size, expression analysis methods, and subject status or race. Here we
brieﬂy review the current knowledge of circRNAs in diﬀerent GI can-
cers.
5.1. Role of circRNAs in gastric cancer
Gastric cancer (GC) is an aggressive disease and despite declining in
prevalence in recent decades, due to improved nutrition, better food
preservation, reduction of H. pylori infection, and earlier diagnosis, it
still remains the fourth most frequent malignancy worldwide, with a
poor prognosis (Ferro et al., 2014). GC is the result of a combination of
environmental factors and an accumulation of genetic alterations
(Carcas, 2014; Sitarz et al., 2018). This cancer is usually diagnosed at
advanced stages, and unfortunately the treatment of advanced and
metastatic cancers has made little progress with a median survival only
around 1 year (Cervantes et al., 2013).
CircRNAs have been proposed to have a key role in GC carcino-
genesis through functioning as a sponge for microRNA and interacting
with RNA binding proteins. To date there have been 13 reported
circRNAs which can act as microRNA sponges in gastric cancer, some of
them can act as tumor suppressors, while others could act as oncogenes
in GC progression (Table 1) (Wang and Dong, 2019). The microarray
expression level analysis of circRNAs in 5 samples of GC in comparison
with adjacent non-tumor tissues showed diﬀerent expression patterns of
713 circRNAs in GC. In GC tissues, 522 circRNAs were down-regulated
whereas 191 were up-regulated, and among them,hsa_circ_0076305,
hsa_circ_0035431, and hsa_circ_0076304showed the greatest alteration
levels. Pathway analysis of diﬀerentially expressed circRNAs revealed
that they were mostly related to carcinogenesis (Dang et al., 2017).
Shen et al. showed 603 down-regulated and 347 up-regulated circRNAs
in GC tissue in comparison to healthy gastric tissue. Further analysis
showed that these circRNAs expression levels did not relate to their host
gene linear mRNA levels, suggesting a diﬀerent mechanism of regula-
tion in the circularization process (Shen et al., 2018). CircRNA ex-
pression analysis using a circRNA chip on 8 GC and normal paired
tissue samples identiﬁed 1285 diﬀerentially expressed circRNAs, 594
were down-regulated and 691 were up-regulated. Functional analysis of
these circRNAs showed that 69 circRNAs could potentially sponge mi-
croRNAs and therefore regulate the target mRNAs. They also suggested
that cancer-related genes such as CD44, CXXC5, MYH9 and MALAT1
could be regulated in GC development through the interaction of cir-
cRNA-miRNA-mRNA pathways (Sui et al., 2017). Another study re-
vealed 16 up-regulated and 84 down-regulated circRNAs in GC. Pre-
diction of interactions between circRNAs and miRNAs targeting speciﬁc
genes revealed that hsa-circ-0026 probably regulates gene silencing,
gene expression, RNA metabolism, RNA transcription and other biolo-
gical activities relevant to GC. They also suggested that hsa_circ-0026
could be a potential biomarker for diagnosing GC as well as for its
targeted therapy (Chen et al., 2017b). In this report, uni-variate and
multi-variate Cox proportional hazard models were used to assess
whether circPVT1 levels were able to predict survival independently
from other pathological and clinical parameters in GC patients. In ad-
dition, if the expression levels of circPVT1 and TNM phase were com-
bined, they could provide a better prognostic indicator compared to the
TNM phase alone. This study also examined the clinical importance of
linear PVT1 expression. Diﬀerently from circPVT1, patients showing
lower levels of PVT1 exhibited better DFS and OS in comparison to the
patients having higher levels of PVT1. When the combined levels of
circPVT1 and PVT1 were examined, patients with lower levels of
circPVT1 and higher levels of PVT1 showed a considerably shorter DFS
and OS compared to patients having higher levels of circPVT1 and
lower levels of PVT1 (Chen et al., 2017b).
736 unique annotated circRNAs were detected by RNA sequencing
in several types of gastric tissues. Further analysis found that ﬁve
microRNAs could be regulated by 5 diﬀerentially expressed circRNAs
out of the 736 totals (Vidal et al., 2017). All of these circRNAs were
previously shown to play roles in GC (Chen et al., 2017b; Shao et al.,
P. Naeli, et al. Critical Reviews in Oncology / Hematology 145 (2020) 102854
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2017; Tian et al., 2018).
In GC cells, hsa_circ_0000993 inhibits invasion as well as pro-
liferation through sponging miR-214-5p (Zhong et al., 2018b). Hsa_-
circ_000146 is negatively associated with survival in GC patients, and
could sponge miR-548 g, which is a tumor suppressor microRNA (Hu
et al., 2014). miR-548 directly targets mRNA, and could reverse the
eﬀects of hsa_circ_000146 overexpression, such as invasion, migration,
and proliferation of GC cells.miR-548 directly targets runt-related
transcription factor 1 (RUNX1),which controls genes expression im-
plicated in the regulation ofcell cycle, the p53 and transforming growth
factor β (TGF- β)signaling pathways (Cai et al., 2015; Chuang et al.,
2013; Sood et al., 2017). Therefore, hsa_circ_000146 was revealed to
act as a tumor suppressor viamodulatingthemiR-548/RUNX1 axis in GC
cells (Fang et al., 2019). It has been also demonstrated that hsa_-
circ_0027599could sponge miR-101-3p, and its overexpression in-
hibited proliferation and metastasis in GC cells. Pleckstrin homology-
like domain family A member 1 (PHLDA1) overexpression, a direct
target of miR-101, decreased the growth and migration of GC cells
(Wang et al., 2018c). Some studies reported pro-apoptotic and anti-
proliferative roles ofPHLDA1, which is involved in drug resistance in
cancer (Fearon et al., 2018; Nagai, 2016). The result of another study
was in contradiction with the above results, since it reported that miR-
101 overexpression inhibited invasion and proliferation in the AGS
gastric cancer cell line (Wu et al., 2017). It seems that clariﬁcation of
the role of miR-101 in GC needs more investigation, and it is worth
distinguishing between the modulatory and regulatory functions of
circRNAs. Knockdown of hsa-circ_001569, which sponges miR-145(a
known tumor suppressor gene in human cancer) decreased cell viability
and promoted apoptosis, while it led to increased miR-145 levels(Shen
et al., 2019).
CircRNAs could sponge RNA binding proteins and decrease their
availability within the cell. A down-regulated circRNAin GC cells called
hsa_circ_104916 could suppress proliferation, invasion and migration
by decreasing the expression of Slug, a transcription factor suppressing
the expression of E-cadherin, and hence modulates the epithelial–me-
senchymal transition (EMT) (Li et al., 2017a). Hsa_circ_104916 over-
expression up-regulated E-cadherin, which could be due to down-
reglation of Slug (Li et al., 2017a).
Recent work has revealed the diﬀerent expression of circRNAs in
GC, and some studies have suggested speciﬁc circRNAs which could be
used as biomarkers in GC diagnosis (Table 2). Hsa_circ_0000190 ex-
pression level was evaluated in 104 GC and adjacent non-tumor sam-
ples, and also in plasma samples from 104GC patients and normal
subjects. The results showed down-regulation of this circRNA in GC,
which could diﬀerentiate patients from normal samples and subjects
with speciﬁcity and sensitivity values of 0.750 and 0.712 respectively
(Chen et al., 2017c). Hsa_circ_002059 expression level was proposed as
a biomarker for GC progression, and it was down-regulated in plasma
samples from 36 post-operative patients in comparison to pre-operative
plasma samples. According to the ﬁndings, Hsa_circ_002059 was down-
regulated in gastric cancer tissues in comparison to the adjacent non-
cancerous tissue. Moreover, it was found that the levels of hsa_-
circ_002059 in plasma collected from post-operative gastric cancer
patients were signiﬁcantly diﬀerent from the levels obtained from pre-
operative gastric cancer patients. Lower levels of expression showed a
signiﬁcant correlation with distant metastasis, TNM stage, and patient
age (Li et al., 2015b). Hsa_circ_0003159 expression was evaluated in
108 paired GC samples, and it was suggested that its down regulation
could be a biomarker in GC (Tian et al., 2018). Hsa_circ_0000467 was
reported to promote cancer progression and was upregulated in GC cell
lines, tissues, and plasma samples from GC patients. It was proposed as
a promising non-invasive marker for GC prognosis as well as diagnosis.
Findings also showed signiﬁcant upregulation of Hsa_circ_0000467 in
GC tissues in comparison to adjacent non-tumor tissues. The same re-
sults were observed in the MGC‐803, HGC‐27, NUGC‐3, AGS, and GES‐1
cell lines and in samples of plasma from GC patients. Results showed
that the area under the ROC curve of hsa_circ_0000467 was 0.790,
which was higher than widely utilized biomarkers such as CA‐724 and
CEA. In addition, the levels of hsa_circ_0000467 expression were sig-
niﬁcantly reduced after surgical operation. Furthermore, a close re-
lationship was found between the expression levels of hsa_circ_0000467
and the TNM phase. Cox multivariate analysis also suggested hsa_-
circ_0000467 could be a new independent prognostic marker. In-vitro
experiments showed that proliferation, migration, and invasion of GC
cells were considerably suppressed by knockdown of hsa_circ_0000467.
In addition, hsa_circ_0000467 silencing resulted in increased tumor cell
apoptosis in-vitro. Therefore, it was suggested that Hsa_circ_0000467
could function as a novel non-invasive biomarker in GC, and could also
be a therapeutic target for GC (Lu et al., 2019a, b). Hsa_circ_KIAA1244
was down-regulated in GC patient plasma, tissues and exosomes, and
was proposed as a diagnostic marker for GC. Its expression status was
related to TNM stage, metastasis and shorter survival rates (Tang et al.,
2018).
5.2. Role of circRNAs in colorectal cancer
Colorectal cancer (CRC) accounts for 10 % of cancer-related deaths,
and is the second and third most frequent malignancy among women
and men, respectively (Marley and Nan, 2016). CRC prevalence has
been increasing in recent decades mainly because of changes in life
style, obesity, low physical activity, smoking, and dietary habits
(Kuipers et al., 2015; Marmol et al., 2017). Most of the hereditary forms
of CRC are caused by mutations in genes, including EPCAM,PMS2,
MSH6, MSH2or MLH involved in DNA mismatch-repair system(Tiwari
et al., 2016), and the adenomatous polyposis coli (APC) gene which
handles the Wnt signaling pathway) (Vasen et al., 2015). Of note,
polyposis is related to mutations in the mutY DNA glycosylase
(MUTYH) gene (Kashﬁ et al., 2013; Markkanen et al., 2013).
The association between CRC and circRNAs was reported for the
ﬁrst time, with the identiﬁcation of a circular transcript of the Deleted
in CRC (DCC)gene (Nigro et al., 1991). As its name suggests the dele-
tion of the DCC gene in CRC had been known for more than two decades
(Fearon and Pierceall, 1995). Bachmayr-Heyda and colleagues
(Bachmayr-Heyda et al., 2015) indicated the global decrease of the
expression of circRNAs in tumor tissues and CRC cell lines in compar-
ison with normal colonic mucosa. They found 39 circRNAs diﬀeren-
tially expressed between CRC samples and normal mucosa. Of these, 28
circRNAs were down-regulatedand11 circRNAs were up-regulated. In-
terestingly, this data agreed with a recent study that also reported the
global decrease of circRNAs in CRC tissues and cell lines (Taborda et al.,
2017). It was hypothesized that circularization is less functional in tu-
mors than in normal tissues, and this could be due to onco-micoRNAs
which are up-regulated in CRC (Ragusa et al., 2015). CircRNA se-
quencing data in two CRC cell lines,SW620(a metastasis-derived cell
line)and SW480 (a primary tumor cell line), and abnormal colorectal
cell, NCM460,showed an overall circRNA abundance decreasein CRC
cell lines in comparison to normal colonic epithelial cells. 2919 cir-
cRNAs that were diﬀerentially expressed between CRC cells and normal
cells were identiﬁed, and it was also found that circRNAs in CRC cells
were usually shorter than those in normal cells (Jiang et al., 2018a).
The circRNAs expression proﬁle from three paired CRC samples and
adjacent non-tumor tissues revealed 136 signiﬁcantly over-expressed
circRNAs and 243 down-regulated circRNAs in CRC tissues. Circ-BANP
was up-regulated in 35 CRC samples and its knockdown attenuated the
proliferation of CRC cells (Zhu et al., 2017). CircRNA-seq analysis in 40
samples of CRC and CRC with liver metastasis (CRC-m) revealed 113
diﬀerentially expressed circRNAs, of which 92 circRNAs were up-
regulated and 21 circRNAs were down-regulated.Hsa_circRNA_0001178
and hsa_circRNA_0000826wereconsiderably up-regulated in CRC-m
tissues. In order to assess the utility of circRNAs as diagnostic bio-
markers, the ROC curves of circRNA_0000826 and circRNA_0001178
were analyzed in CRC-m patients with liver metastasis. The results
P. Naeli, et al. Critical Reviews in Oncology / Hematology 145 (2020) 102854
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showed increased expression levels of circRNA_0000826 and cir-
cRNA_0001178 in patients with CRC-m. The ROC curves were analyzed
for assessing the diagnostic value of both circRNAs in CRC-m patients.
The analysis showed that AUC was 0.816 for circRNA_0000826 and
0.945 for circRNA_0001178. The mentioned circRNAs could be pro-
mising markers for the diagnosis of liver metastasis from CRC (Xu et al.,
2019a).
Expression pattern analysis has shown signiﬁcantly higher hsa_-
circ_001569 expression in CRC, which was related to aggressive fea-
tures such as metastasis (Taborda et al., 2017). Over-expression of
hsa_circ_001569 increased invasion as well as proliferation in the CRC
cell lines, while its suppression showed a remarkable decrease in in-
vasiveness and proliferation rate. It has also been shown that hsa_-
circ_001569 sponges miR-145 leading to increased protein levels of
formin like 2 (FMNL2), “B-cell lymphoma 2 associated athanogene 4”
(BAG4), and E2F5 (Taborda et al., 2017). E2F5 is a transcription factor
regulating the expression of genes implicated in the cell cycle (Jiang
et al., 2011). BAG4 and FMNL2 are implicated in invasion and growth
as well as metastasis (Annunziata et al., 2007; Li et al., 2010; Liang
et al., 2013). MiR-145 has been reported to be correlated with survival
in patients with CRC (Li et al., 2012), and also inhibits invasion and
migration in CRC cell lines (Sheng et al., 2017). Hsa_circ_001988 down-
regulation was reported in CRC tissues compared with adjacent normal
mucosa in 62 patients, and its expression level was related to diﬀer-
entiation and invasion (Wang et al., 2015). Hsa_circ_0000069 was sig-
niﬁcantly up-regulated in 30 paired CRC samples and non-tumor ad-
jacent tissues (Guo et al., 2016). The knockdown of hsa_circ_0000069
can inhibit invasion, migration, and proliferation of tumor cells.
CircCCDC66 expression was elevated in CRC and was associated with
poor prognosis. CircCCDC66 could function as an oncogene and its
knockdown signiﬁcantly reduced cell migration and metastasis (Hsiao
et al., 2017). Evaluation of ciRS-7-A in 44 matched healthy mucosal
samples and 153 primary CRC tissues revealed that this biomarker was
remarkably up-regulated in cancer tissues (Weng et al., 2017). CiRS-7
over-expression led to miR-7 suppression, and the RAF1 and EGFR
oncogene activation, and was also correlated with poor patient survival.
Cir-ITCH was found to be down-regulated in 45 CRC tissues in com-
parison to adjacent non-tumor tissues (Huang et al., 2015). Functional
analysis showed that cir-ITCH increases ITCH levels implicated in the
Wnt/β-catenin pathway suppression. Therefore, cir-ITCH may play a
key role in CRC through modulating the Wnt/β-catenin pathway.
A summary of the circRNAs that have been reported to be involved
with CRC is shown in Tables 3 and 4.
5.3. Role of circRNAs in esophageal cancer
Esophageal cancer (EC) has an overall ﬁve-year survival ranging
from 15 % to 20 %, and is the eighth most frequent malignancy in the
world, and the sixth most prevalent cause of cancer-related mortality.
The two histological subtypes of EC are squamous cell carcinoma and
adenocarcinoma, that each has varying geographical and racial dis-
tribution (Abbas and Krasna, 2017; Sohda and Kuwano, 2017). The risk
factors for EC are abuse of tobacco and alcohol, obesity, diet, race and
gender (Domper Arnal et al., 2015). EC continues to be a generally fatal
disease with only a modest improvement in survival, and surgery still
plays the main role in EC treatment (D’Journo and Thomas, 2014). The
poor prognosis in EC is mainly because of late diagnosis, and more than
50 % of patients already had metastatic tumor at the time of diagnosis
(D’Journo and Thomas, 2014). Identifying a biomarker for the detec-
tion of EC at an early stage is crucial to improve disease management.
Accumulating evidence suggests that circRNAs have a crucial role in
EC (Table 5). Microarray analysis of circRNAs in esophageal squamous
cell carcinoma (ESCC) and adjacent-cancer tissues in three patients
revealed 3288 diﬀerentially expressed circRNAs of which 2139 were
up-regulated, and 1149 were down-regulated. Further network analysis
of circRNAs-mRNA-microRNA interactions showed that 32
diﬀerentially expressed circRNAs and 98 diﬀerentially expressed
mRNAs were linked to 64 miRNAs in ESCC (Jiang et al., 2019b). The
expression pattern of the circRNAs revealed that 1045 were up-regu-
lated and 1032 were down-regulated in 3 pairs of frozen tumor and
non-tumor ESCC tissues. Three circRNAs including hsa_circ_0043603,
hsa_circ_0001946, andhsa_circ_0062459 were detected in plasma, and
the combination of hsa_circ_0043603 and hsa_circ_0001946 could be
utilized as a diagnostic biomarker with sensitivity of 0.928 and speci-
ﬁcity of 98 %.The ﬁndingsdemonstratethat these two circRNAs could be
utilized as diagnostic biomarkers.
A circular RNA micro-array was employed to analyze three pairs of
ESCC frozen tumor and non-tumor tissue in order to detect ESCC-as-
sociated circRNAs. A total of 1045 up-regulated and 1032 down-regu-
lated circRNAs were observed, among which six circRNAs (hsa_-
circ_0062459, hsa_circ_0076535, hsa_circ_0072215, hsa_circ_0042261,
hsa_circ_0001946, and hsa_circ_0043603) were conﬁrmed by qRT-PCR
analysis. Because blood is the most widely utilized sample in the la-
boratory, these six circRNAs were also investigated in blood as diag-
nostic biomarkers. The results indicated there were no detectable levels
of hsa_circ_0042261, hsa_circ_0072215, or hsa_circ_0076535 in the
plasma or serum of either patients or healthy individuals. ROC curve
analysis was used to assess the speciﬁcity and sensitivity of the other
three circRNAs. The AUCs of hsa_circ_0001946 and hsa_circ_0062459
respectively were 0.894 (sensitivity= 92 %, speciﬁcity= 80 %) and
0.836 (sensitivity= 64 %, speciﬁcity= 92 %) respectively. A logistic
regression analysis was run to establish the whether a combination of
the expression levels of both circRNAs in plasma was useful. The for-
mula was established as 3.272-(0.465*level of hsa_circ_0001946) –
(1.706* level of hsa_circ_0062459). Logistic regression analysis showed
better diagnostic precision with the combination AUC, speciﬁcity of 98
% and sensitivity of 0.928. Moreover, hsa_circ_0001946 over-expression
decreased invasion, migration, and proliferation in cell lines (Fan et al.,
2019).
Another study reported that 267 circRNAs revealed considerably
diﬀerent levels of expression in ESCC tissues from ﬁve patients and
adjacent non-tumor tissues (Jiang et al., 2019b). Of these circRNAs, 92
were up-regulated and 175 were down-regulated. Hsa_-
circRNA_406826and hsa_circRNA_101125 were proposed as novel po-
tential markers for ESCC treatment and diagnosis. Another study
identiﬁed 813 signiﬁcantly up-regulated and 445 down-regulated cir-
cRNAs in normal epithelial and malignant esophageal cell lines (Sun
et al., 2017). The ﬁve most up-regulated circRNAs were ciRNA11, cir-
cRNA904, circRNA3594, ciRNA101, circRNA1241, and the top ﬁve
most down-regulated circRNAs were circRNA9864, circRNA9650, cir-
cRNA9865, circRNA9671 and circRNA9930. Pathway analysis showed
that diﬀerentially expressed circRNAs were linked to cancer-related
pathways including metabolism, cell apoptosis, proliferation and mi-
gration.
Evaluation of circRNA expression in ESCC using microarray tech-
nology revealed that 469 circRNAs were up-regulated, and 275 were
down-regulated in ESCC in comparison with non-tumor adjacent tissue.
Of these, the most up-regulated (increased 20.3-fold) circRNA was
hsa_circRNA_103670, while the most down-regulated (decreased 12.1-
fold) was hsa_circRNA_030162 (Shi et al., 2018).
In addition to proﬁling circRNAs in EC, there have been some re-
ports, which have explored the expression of speciﬁc circRNAs in EC,
and clariﬁed their roles in vitro. Hsa_circ_0067934 was signiﬁcantly up-
regulated in 51 paired ESCC samples in comparison to the adjacent
normal tissues. SiRNA inhibition of hsa_circ_0067934 blocked migra-
tion and proliferation, and suppressed the progression of cell cycle in
ESCC cells (Xia et al., 2016). Cir-ITCH expression status was analyzed in
a total of 684 ESCC and paired adjacent non-tumor tissue samples and
its overall down-regulation was established in ESCC samples (Li et al.,
2015a). Cir-ITCH sponges miR-7, -17, and -214. In addition, Cir-ITCH
probably exerts its suppressive eﬀects on ESCC through modulating the
Wnt/β-catenin signaling pathway. The circ-TTC17 expression levels
P. Naeli, et al. Critical Reviews in Oncology / Hematology 145 (2020) 102854
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were observed to be greater in ESCC plasma and tissue from ESCC
patients in comparison to healthy subjects. The ROC curves were uti-
lized for investigating the diagnostic value of circ-TTC17 in diﬀer-
entiating ESCC samples from normal plasma. As shown by the analysis,
the cutoﬀ value of circ-TTC17 was –2.548, and the area under the ROC
curve (AUC) was 0.8200. Moreover, this showed a sensitivity of 73.33
% and a speciﬁcity of 88.00 %. In addition, a positive relationship was
observed between the expression of circ-TTC17 and the TNM phase and
the presence of lymphatic metastasis. Kaplan–Meier survival analysis
and log-rank statistics were used to compare patient postoperative
survival and the expression levels of circ-TTC17 for the prognosis of
ESCC patients. The ESCC patients with higher levels of circ-TTC17 ex-
pression demonstrated a considerably shorter survival time in com-
parison to patients with lower levels of circ-TTC17 expression. Uni-
variate analysis revealed that the TNM phase, relative circ-TTC17
expression level, and lymphatic metastasis were all prognostic indices
for OS rates of ESCC patients. Nevertheless, multi-variate analyses of
the variance showed that only the size of the tumor was an independent
marker to assess the prognosis of the ESCC patients. Hence, circ-TTC17
has potential to be utilized as a prognostic and diagnostic marker for
ESCC. Circ-TTC17 can act as an oncogene, and promote ESCC cell
proliferation and migration. Bioinformatics analysis suggested that circ-
TTC17 could play a role in ESCC by sponging microRNAs such as miR-
153, -217, -224, and -370 (Wang et al., 2019d).
It was observed that hsa_circ_0004370 was up-regulated in both EC
tissues and cell lines. Interestingly, loss of hsa_circ_0004370 function
suppressed invasion as well as proliferation of EC cell lines and in-
creased their apoptosis rate. Hsa_circ_0004370 can sponge miR-1294
and indirectly increase the level of “LIM and SH3 domain protein 1”
(LASP1) suggesting that hsa_circ_0004370 can function as an oncogene
aﬀecting proliferation, apoptosis, and invasion via the miR-1294/
LASP1 axis (Zhang et al., 2019c). LASP1 enhances tumor invasion as
well as proliferation in various cancers and could act as an essential
EMT mediator by mediating the mitogen-activated protein kinase
(MAPK) phosphorylation, triggering Smad and PI3K/AKT pathways
(Wang et al., 2014; Zhang et al., 2017c). Circ-SMAD7 derived from the
gene SMAD7 intron, is remarkably downmodulated in plasma samples
from ESCC patients in comparison with healthy subjects, and showed a
negative correlation with the TNM stage. in vitro circ-SMAD7 over-
expression could suppress migration and proliferation in ESCC cells,
while circ-SMAD7 knockdown showed the opposite eﬀects. Taken to-
gether these ﬁnding suggested a tumor suppressor role for circ-SMAD7
in ESCC (Zhang et al., 2019b). Functional analysis of circ0043898
shown to be downmodulated in ESCC tissue samples, indicating its in-
hibitory eﬀects on invasion, migration, and proliferation of tumor cells,
and could induce apoptosis in ECA-109 and Kyse-520 ESCC cells. in vivo
experiments showed that circ0043898 was associated with inhibition of
oncogenesis (Guo et al., 2018). Besides playing a role in carcinogenesis,
circRNAs could be involved in other aspects of cancer, such as the de-
velopment of drug and radiation resistance. Evaluation of circRNAs
found signiﬁcant up-regulation of 57 circRNAs and down-regulation of
17 circRNAs in KYSE-150R, a radioresistant EC cell line, compared with
the radiosensitive KYSE-150 (Su et al., 2016).
5.4. Role of circRNAs in hepatocellular carcinoma
Hepatocellular carcinoma (HCC) is increasing in incidence world-
wide with an average survival rate between 6–20 months (Waller et al.,
2015). HCC is more common among males, with a male: female ratio of
2.4 worldwide, and the most common age at presentation is between
the third and ﬁfth decades of life (Kulik and El-Serag, 2019). Chronic
liver diseases caused by hepatitis B and C viruses, and excessive con-
sumption of alcohol contributes most to the HCC subjects (Ghouri et al.,
2017). HCC pathogenesis involves diﬀerent genetic aberrations, and
alterations in several signaling pathways, which lead to a heterogeneity
in the disease at a molecular level (Bertino et al., 2014). An improved
knowledge of the molecular mechanisms of hepatocarcinogenesis could
help to improve diagnostic methods, and enable possible therapeutic
strategies to inhibit cancer-driving signaling pathways.
Mounting data suggests that circRNAs are related to HCC develop-
ment (Tables 6 and 7), but their mechanism of action in the develop-
ment of HCC remains unclear. Shang et al. analyzed circRNA expression
in 3 paired HCC and non-tumor tissues, and identiﬁed 61 diﬀerentially
expressed circRNAs. Among them, 26 circRNAs were up-regulated and
35 were down-regulated in tumor cells. Additionally, they reported that
hsa_circ_0005075 levels were considerably up-regulated in HCC, was
associated with HCC tumor size, and could be used as potential bio-
marker with sensitivity of 83.3 %and speciﬁcity of 90.0 %. Bioinfor-
matics analysis of the circRNA-miRNA-mRNA interaction network
predicted that a total of 4 miRNAs and 121 mRNAs could interact with
hsa_circ_0005075 (Shang et al., 2016). Micro-array analysis detected
twenty speciﬁc circRNAs with diﬀerential expression levels between
tumor and non-tumor tissues. qRT-PCR was employed to verify the
expression levels of the above 20 circRNAs. Moreover, the micro-array
test results showed that hsa_circ_0091579 mRNA and hsa_circ_16245-1
expression was consistent with the respective levels. However, because
the levels of hsa_circ_16245-1 and hsa_circ_0091579 were signiﬁcantly
enhanced in the HCC tissues, it was decided to evaluate their potential
diagnostic value. ROC curves were obtained for hsa_circ_0091579 and
hsa_circ_16245-1 levels in HCC. The areas under the ROC curve were
Table 4
CircRNAs as biomarkers in colorectal cancer.
circRNAs Dysregulation miRNA sponge Related molecules or
pathways
Model Type of cell line Ref
hsa_circRNA_104700 Down – – Human – (Zhang et al., 2017b)
circRNA0003906 Down – – Human In vitro SW480, HCT8, SW620, LoVo, HT29, HCT116 (Zhuo et al., 2017)
circ_0026344 Down miR-31, miR-21 – Human – (Yuan et al., 2018)
hsa_circ_001988 Down – – Human – (Wang et al., 2015)
hsa_circ_0000567 Down – – Human In vitro SW480, SW620, RKO, HCT116, CACO2 (Wang et al., 2018b)
Hsa_circ_0014717 Down – p16 Human In vitro HCT116, SW480, HT29 (Wang et al., 2018a)
hsa_circ_0000711 Down – – Human In vitro HCT116, HT29, COLO205 (Li et al., 2018a,
2018b)
circITGA7 Down miR-307-3p ITGA7 Human In vitro SW480, Caco-2, RKO, SW620, HCT116,
LoVo, DLD1
(Li et al., 2018f, g)
hsa_circ_0001649 Down – – Human In vitro H116 (Ji et al., 2018)
hsa_circ_0136666 Up miR‐136 SH2B1 Human In vitro LoVo, DLD1, SW480, SW620, HCT116, HCT8,
HT29
(Jin et al., 2019)
circCCDC66 Up – – Human In vitro – (Hsiao et al., 2017)
circRNA_100290 Up miR-516b FZD4 Human In vitro HCT116, HT29, SW480, SW620 (Fang et al., 2018)
circHIPK3 Up miR-7 FAK, YY1, IGF1R, EGFR Human In vitro HT29, HCT116 (Zeng et al., 2018)
ciRS-7 Up miR-7 EGFR/RAF1 Human In vitro HCT116, HT29 (Weng et al., 2017)
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0.720 for hsa_circ_16245-1 and 0.656 for hsa_circ_0091579. For hsa_-
circ_0091579, the sensitivity and speciﬁcity were 0.4 and 0.97 respec-
tively. The speciﬁcity and sensitivity of hsa_circ_16245-1 were 0.63
0.83 respectively. 75 pairs of HCC specimens were tested to validate the
prognostic value of these circRNAs. Hsa_circ_0091579 expression was
remarkably increased in HCC tumor tissue in comparison to the levels
in adjacent non-tumor tissues. They could not detect hsa_circ_16245-1
in a number of the HCC samples. Thus, hsa_circ_0091579 up-regulation
serves as a potential prognostic marker for individuals with HCC, and is
related to overall survival (Zhang et al., 2018a). Hsa_circ_0001649 ex-
pression was considerably down-modulated and was correlated with
tumor size in 89 HCC tissues in comparison to adjacent non-tumor
tissues (Qin et al., 2016). Microarray analysis of circRNAs revealed that
the expression of hsa_circ_0004018 was lower in HCC than non-tumor
tissues. Hsa_circ_0004018 expression was also associated with TNM
stage, diﬀerentiation, and tumor diameter (Fu et al., 2017b).
The microRNA sponging function of circRNAs is involved in HCC
development, and various pathways have been reported to be regulated
by this mechanism. circMTO1 (mitochondrial translation optimization1
homologue) and hsa_circRNA_0007874/hsa_circRNA_104135 were de-
tected to be remarkably down-modulate in HCC tissues, and were
linked to shortened survival. MiR-9 was found to bind tocircMTO1, and
circMTO1 silencing in HCC cells could down-modulate p21, the onco-
genic miR-9 target, leading to HCC invasion and proliferation promo-
tion. Furthermore, an inhibitor of miR-9 blocked the tumor-promoting
impact of circMTO1 silencing (Han et al., 2017). The expression of
CircTRIM33–12 in HCC tissues was investigated, and it was revealed
that circTRIM33–12 is down-regulated in HCC cell lines and tissues.
CircTRIM33-12 can sponge miR-191, and its inhibition increased im-
mune evasion, tumor invasion, migration, and proliferation (Zhang
et al., 2019a). Compared to the adjacent non-tumor tissues, Cdr1as
expression is up-regulated in HCC tissues, and its suppression inhibits
miR-7 expression and increased tumor cells invasion and proliferation.
Mentioned ﬁndings propose that Cdr1as acts as an oncogene in HCC,
partly by targeting miR-7 (Yu et al., 2016). Expression analysis of cir-
cRNA-101368 showed that this circRNA is considerably up-modulated
in HCC tissue samples, and the higher expression of hsa-circ-101368
was related to poor prognosis in patients with HCC. Hsa-circ-101368
was conﬁrmed that directly binds to miR-200a and both could nega-
tively modulate each other. The expression of miR-200a was negatively
related to hsa-circ-101368 expression in tissue samples. Hsa-circ-
101368 inhibition blocked migration, which could be partially atte-
nuated via miR-200a suppression (Li et al., 2018d).
CircSETD3 (hsa_circRNA_101436/hsa_circRNA_0000567) was re-
markably down-regulated in HCC cell lines and tissues, and was cor-
related with larger tumor size and poor HCC diﬀerentiation in aﬀected
subjects. CircSETD3 could suppress the proliferation of HCC cells and
induced G1/S cell cycle arrest. Furthermore, it was shown that
circSETD3 could act as a sponge for miR-421, which targets MAPK14
signaling (Xu et al., 2019b). MAPK14 may facilitate tumor cells pro-
liferation and survival, and contribute to the progression of some tumor
types (Igea and Nebreda, 2015).Yu et al. reported that hsa-circ-104718
was physically associated and co-expressed with microRNA-218-5p in
HCC. They found that exogenously expressed hsa-circ-104718 ac-
celerated cell proliferation, migration, invasion, and inhibited apop-
tosis. Hsa-circ-104718 over-expression could increase tumor size and
metastasis, while its silencing had the opposite eﬀect. Conversely, miR-
218-5p over-expression could decrease the proliferation, migration,
invasion, and increase apoptosis (Yu et al., 2019).
5.5. Role of circRNAs in gallbladder cancer
Gallbladder cancer (GBC), the most prevalent biliary tract cancer,
accounts for more than 80 % of biliary tract malignancies (Lai and Lau,
2008). GBC has only a 6 month mean overall survival, while the 5-year
survival rate remains low at about 5 %. A genetic predisposition,Ta
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congenital biliary tract anomalies, female sex, and age are considered to
be the main risk factors for GBC development. Based on the geo-
graphical and ethnical considerations, the mentioned factors are dif-
ferent among populations (Hundal and Shaﬀer, 2014). This malignancy
is most often diagnosed at late stages, frequently proving fatal. Al-
though surgical resection is the only treatment option, only 10 % of
aﬀected subjects are candidates for surgery with curative intent at in-
itial presentation (Kanthan et al., 2015). The development of diagnostic
markers is essential for improved GBC management, and could lead to
the development of screening programs for individuals at risk.
Some evidence has shown that circRNAs are involved in GBC de-
velopment. However, much remains unknown about the role of
circRNAs in GBC, and further investigation is needed to clarify possible
circRNA regulatory pathways in the initiation and development ofGBC.
CircHIPK3 was found to be up-regulated in human GBC cells. Silencing
of circHIPK3 using siRNA, induced apoptosis and suppressed pro-
liferation and survival of both primary and established human GBC
cells. The opposite eﬀects occurred with circHIPK3 over-expression (Xu
et al., 2013). Further investigation showed that circHIPK3 could sponge
tumor-suppressive microRNA-124 resulting in enhanced miR-124 gene
targets expression, such as CDK6 (rho-associated protein kinase) and
ROCK1 (rho-associated protein kinase 1) (Pierson et al., 2008). They
concluded that, through sponging miR-124, circHIPK3 could promote
GBC cell growth (Kai et al., 2018). CircHIPK3 was also observed to
sponge miR-379, and miR-379 up-regulation rescued the phenotype
induced by over-expression of circHIPK3 (Tian et al., 2017).
5.6. Role of circRNAs in pancreatic cancer
Pancreatic cancer is the fourth most frequent cause of malignancy-
associated mortality in USA. Although the approaches for management
and detection of this cancer have been developed, 5-year survival re-
mains at only 4 %. The lethality is mainly caused by its propensity to
rapidly metastasize to the lymphatic system and distant organs
(Iovanna et al., 2012). The main risk factors for developing pancreatic
cancer are high-fat diet, African-American ethnic origin, obesity, dia-
betes mellitus, male sex (Vincent et al., 2011), smoking, age, and family
history of chronic pancreatitis (Klein et al., 2004). Up to now, surgical
resection is the only therapeutic approach for pancreatic cancer, and it
responds poorly to chemotherapeutic agents (McGuigan et al., 2018).
Understanding the underlying mechanism contributing to pancreatic
cancer is essential to develop new treatment strategies.
Studies have suggested that circRNAs could serve as diagnostic or
predictive biomarkers for pancreatic cancer, and could provide new
insights especially in pancreatic ductal adenocarcinoma (PDAC) (Tables
8 and 9) (Qu et al., 2015). Microarray analysis of circRNAs in 6 PDAC
and paired non-tumor tissues revealed that 351 circRNAs were diﬀer-
entially expressed between PDAC and the healthy tissue, of which 142
circRNAs were down-regulated and 209 circRNAs were up-regulated in
tumor samples. Some diﬀerentially expressed circRNAs were evaluated
by qRT-PCR in 20 paired tissues. Bioinformatics analysis predicted that
hsa_circ_0005785 (one of the diﬀerentially expressed circRNAs) was
potentially able to bind miR-181a and miR-181b (Li et al., 2016a). MiR-
181a has a crucial role in modulating the migration as well as growth of
pancreatic cancer cells (Zhang et al., 2015). MiR-181b is related to
pancreatic cancer cell resistance to gemcitabine chemotherapy
(Takiuchi et al., 2013). Gue et al. investigated the circRNA proﬁle in 20
pancreatic cancer tissues and corresponding adjacent tissues. They re-
ported that 128 circRNAs were up-regulated and 161 circRNAs were
down-regulated in cancer tissues (Guo et al., 2018). Moreover, these
authors predicted circRNA-miRNA interactions, and identiﬁed eight
circRNAs that bound to miR-15a.Three of these were up-regulated
(hsa_circ_100435, hsa_circ_103076, hsa_circ_103309) and ﬁve were
down-regulated (hsa_circ_000780, hsa_circ_101252, hsa_circ_102374,
hsa_circ_104433, hsa_circ_104882).Moreover, four up-regulated cir-
cRNAs bound to miR-506 (hsa_circ_101717, hsa_circ_104084,Ta
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hsa_circ_100646, hsa_circ_102213). It has been reported that miR-15a
could inhibit the proliferation of pancreatic cancer cells and the EMT,
and that miR-506 could suppress progression and chemoresistance (Guo
et al., 2014b; Li et al., 2016b). Gue et al. speculated that circRNAs could
regulate gene expression via the miRNA sponging eﬀect and may have a
role in the progression of pancreatic cancer (Guo et al., 2018).
Hsa_circ_0006215 was shown to be remarkably up-regulated in
pancreatic cancer tissue. Based on bioinformatics analysis, it was pro-
posed that hsa_circ_0006215 most likely regulated the expression of
miR-378a-3p (Zhu et al., 2018a). Expression analysis of circ-IARS in
human microvascular vein endothelial (HUVECs) cells, Hs 766 T, Hs
766 T-L2 pancreatic cancer cells, plasma exosomes, and PDAC tissues
revealed that the expression of circ-IARS is up-modulated in plasma
exosomes and in pancreatic cancer cells/tissues of metastatic disease
patients (Zhang et al., 2018a). Also, the expression of circ-IARS is po-
sitively linked to TNM stage, vascular invasion and liver metastasis, and
negatively associated with postoperative survival time. Circ-IARS
sponges miR-122, and its overexpression considerably down-regulates
miR-122. Taken together, it was proposed that circ-IARS promotes
tumor metastasis and invasion (Zhang et al., 2018a). The expression of
ciRS-7 and MiR-7 in 41 pairs of PDAC tumors and their adjacent tissues
revealed that the expression of ciRS-7 is remarkably greater in PDAC
tissue. However, the expression of miR-7 demonstrated the conﬂicting
trend. Moreover, ciRS-7 suppression inhibits invasion and proliferation
of PDAC cells. Using functional analysis they proposed an oncogenic
role for ciRS-7 in PDAC, which could act partially through modulating
the EGFR/STAT3 pathway as well as targeting miR-7 (Liu et al., 2019a).
Qu and colleagues indicated that circRHOT1 was up-regulated in pan-
creatic cancer. CircRHOT1 could bind to miR-382, -330, -125a, and
-26b, leading to modulate various tumor-related pathways. Moreover,
circRHOT1 knockdown could inhibit pancreatic cancer cell prolifera-
tion, invasion and migration (Qu et al., 2019).
Gemcitabine (2',2'-diﬂuoro 2'-deoxycytidine, dFdC) (a cytidine
analogue) is a cornerstone of PDAC therapy at all stages. Unfortunately,
chemoresistance development within weeks of treatment initiation has
limited its clinical use (Amrutkar and Gladhaug, 2017). Shao et al. re-
ported that the circRNA signature was diﬀerent between the gemcita-
bine-resistant PANC-1-GR cell line and the gemcitabine-sensitive PANC-
1 counterpart (Shao et al., 2018). Diﬀerential analysis of gene expres-
sion between PANC-1 and PANC-1-GR cells showed that 126 circRNAs
had signiﬁcantly diﬀerent expression between these two cell lines, with
68 up-regulated and 58 down-regulated in PANC-1-GR cells in com-
parison with PANC-1 cells. In another investigation, the expression le-
vels of circ-LDLRAD3 were examined in 31 plasma samples from
normal cases 31 plasma samples from pancreatic cancer patients, cell
lines and 30 paired pancreatic cancer and adjacent non-tumor tissues
(Yang et al., 2017). Their results showed that Ccirc-LDLRAD3 is up-
regulated in plasma samples tissues and cell lines of pancreatic cancer.
Besides, the expression of circ-LDLRAD3 is signiﬁcantly associated with
metastasis, as well as venous and lymphatic invasion.
6. Conclusions
CircRNAs, once thought to be merely random errors in transcrip-
tion, have now been realized to be important players in cell biology and
regulation of gene expression. The mechanism by which they regulate
gene expression, and their overall function are not yet fully understood.
Recent studies have clariﬁed that these transcripts are dysregulated in
many cancers, and play an essential role in cancer-related signaling
pathways. Taken together, these ﬁndings highlight the important and
diverse role of circRNAs in cancer initiation and progression.
Accumulating evidence suggests that one important mechanisms of
action for circRNAs is by acting as microRNA sponges, thus having the
opposite eﬀect on gene expression as manifested by the corresponding
miRNAs involved. The present review has shown that circRNAs are
involved in many diﬀerent GI cancers, including esophagus, stomach,Ta
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pancreas, liver, gallbladder and colorectal cancer. The fact that these
cancers arise from several diﬀerent cell types and have diﬀerent risk
factors for cancer development, underlines the likelihood that circRNAs
may be involved in general signaling pathways in cancer, such as cell
cycle regulation, cell death, proliferation, migration and metastasis. On
the other hand, some circRNAs show tissue or malignancy-speciﬁc ex-
pression patterns, and may function in a single type of cancer or even a
single-subtype. The fact that expression levels of many circRNAs can be
detected in serum or plasma samples encourages the development of
non-invasive screening or biomarker studies. High-throughput
screening of thousands of circRNAs together with sophisticated com-
puter algorithms may allow prognostic predictions, and monitoring of
the development of treatment resistance. Inhibitors (small molecules or
nucleic acid-based) of those circRNAs that function as oncogenes may
be developed in the future. Clarifying the roles of circRNAs in GI can-
cers could open a new window in management and the development of
new therapeutic strategies. Further investigation in the ﬁeld of
circRNAs and cancers is needed to fully characterize their role in car-
cinogenesis.
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